恩瑞格治疗铁质积聚的效果

(Deferasirox) is a new type of active iron chelator that is highly selective with iron (Fe3+). Enrig can be taken for a long time. In addition to chelating intracellular iron, Enrig is also related to the increase of hepcidin, which can reduce the iron absorption of intestinal cells, so the iron removal effect is better. Today we will learn more about the effect of Enrig in treating iron accumulation.

The results of a single-arm, multi-center, prospective clinical study enrolling 64 AA patients with transfusion-related iron overload confirmed the effectiveness and safety of Enrig (deferasirox) in reducing patients' ferritin levels. A prospective, observational study in my country using liver, pancreas, and heart as monitoring indicators confirmed that Enrig can improve organ function in patients with iron overload. The results of the TELESTO study released at the ASH 2018 meeting also proved that Enrige continuously reduces serum ferritin levels, while reducing the risk of heart function damage, liver function damage, transformation to leukemia and other events by 36.4%.

In summary, iron overload increases the risk of infection, endocrine system damage, vital organ dysfunction, AML transformation in MDS patients, and shortens survival. Iron chelators are currently the mainstream treatment for iron removal. Among them, Enrig (deferasirox) is easy to administer, significantly reduces ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment.

Enrig (deferasirox) dispersible tablets can be used for patients with iron accumulation due to long-term blood transfusion (such as thalassemia or other rare anemias). It is suitable for children over two years old and adults. Corresponding to body weight, it is initially recommended to take 20 mg/kg of Enrige daily, depending on the improvement of serum ferritin indicators.

Enrig (deferasirox) dispersible tablets are oral active chelating agents that are highly selective for iron (Fe3+). It is a ligand with 3 protrusions that binds iron with high affinity in a 2:1 ratio. Although Enriga has a very low affinity for zinc and copper, the concentrations of these trace metals in serum decreased to varying degrees after administration. The clinical significance of these reductions in metal concentrations is unclear. It should be noted that Enrig dispersible tablets should be used with caution in patients with reduced liver and kidney function, elderly patients, pregnant and lactating women, and children under 6 years old; children under 2 years old should not use it.

The above is the content of the therapeutic effects of (deferasirox), I hope it can help you!

Recommended related hot articles: /newsDetail/80956.html